Nippon Shinyaku Co., Ltd.’s failed confirmatory trial for the Duchenne muscular dystrophy treatment Viltepso (viltolarsen) is sure to reignite questions about the use of dystrophin as a basis for accelerated approval, as well as the ability of selected functional endpoints to detect change in the disease.
On 27 May, Nippon Shinyaku announced that RACER53, a Phase III, placebo-controlled study of 77 boys with ambulatory DMD, failed...








